Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Abcam
Abcam
Activities:
Research & Development
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
Therapeutic: ensifentrine for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants
A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
Bringing biotech to the Baltics: the rise of Lithuania
Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Research & Development
Danaher set to acquire antibody company Abcam
The two companies have entered an agreement whereby Danaher is set to acquire biotechnology company Abcam's shares for $24 per share
Manufacturing
Avacta signs distribution agreement with Abcam
Abcam supplies biological reagents and kits used in a wide range of fields including drug discovery, diagnostics and basic research
Finance
Axol Bioscience and Censo Biotechnologies announce merger
Under the terms of the agreement, Axol CEO, Liam Taylor, and the company’s senior leadership team will take over the management of the combined entity
Finance
Abingdon Health signs co-marketing agreement with Abcam
Under the terms of the agreement, Abcam will be the preferred supplier to Abingdon of gold nanoparticles and custom conjugation reagents and services
Finance
Abcam opens cell engineering facility in Bay Area
This development builds upon Abcam’s previous acquisition of a range of knockout cell lines from Edigene last year
Ingredients
Abcam offers bioactive proteins for drug discovery
Sourcing high-quality proteins with batch-to-batch consistency can be a challenge, as endotoxin levels and/or non-native protein conformations and post-translational modifications can affect safety and performance
Manufacturing
John Baker: life sciences need to address the reproducibility crisis
The head of product innovation at Abcam says it is crucial that the whole industry finds ways to de-risk the route to the patient as early as possible
Subscribe now